These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29335868)

  • 1. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
    Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
    Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.
    Hwang J; Kim YK; Min JH; Choi SY; Jeong WK; Hong SS; Kim HJ; Ahn S; Ahn HS
    Eur Radiol; 2017 Nov; 27(11):4581-4590. PubMed ID: 28500365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance.
    Min JH; Kim YK; Sinn DH; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Kim MJ
    Abdom Radiol (NY); 2018 Sep; 43(9):2309-2320. PubMed ID: 29470629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
    Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
    Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.
    Park HJ; Jang KM; Kang TW; Song KD; Kim SH; Kim YK; Cha DI; Kim J; Goo J
    Eur Radiol; 2016 Sep; 26(9):3102-11. PubMed ID: 26634931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.
    Haradome H; Unno T; Morisaka H; Toda Y; Kwee TC; Kondo H; Sano K; Ichikawa T; Kondo F; Sugitani M; Takayama T
    Eur Radiol; 2017 Nov; 27(11):4461-4471. PubMed ID: 28439650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.
    Zheng W; Huang H; She D; Xiong M; Chen X; Lin X; Cao D
    Abdom Radiol (NY); 2022 Mar; 47(3):957-968. PubMed ID: 34964069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma.
    Park MJ; Kim YK; Park HJ; Hwang J; Lee WJ
    J Comput Assist Tomogr; 2013; 37(6):872-81. PubMed ID: 24270108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid-enhanced MR Imaging and Dynamic CT.
    Choi SH; Lee SS; Kim SY; Park SH; Park SH; Kim KM; Hong SM; Yu E; Lee MG
    Radiology; 2017 Mar; 282(3):771-781. PubMed ID: 27797675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
    Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Gu KW; Kim YK; Min JH; Ha SY; Jeong WK
    Abdom Radiol (NY); 2017 May; 42(5):1424-1433. PubMed ID: 28078380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
    Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
    AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Wang LF; Guan X; Shen YT; Zhou BY; Sun YK; Li XL; Yin HH; Lu D; Ye X; Hu XY; Yang DH; Xia HS; Wang X; Lu Q; Han H; Xu HX; Zhao CK;
    Abdom Radiol (NY); 2024 Feb; 49(2):458-470. PubMed ID: 38225379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
    Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
    Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.